Skip to main content

How I do it: Apalutamide use in non-metastatic castrate resistant prostate cancer.

Publication ,  Journal Article
Moul, JW
Published in: Can J Urol
June 2019

Urologists have been using oral nonsteroidal antiandrogens (AA) for 30 years as a component of combined androgen blockade. In February 2018, a new third generation AA, apalutamide, became available for the first time for non-metastatic (M0) castrate resistant prostate cancer (CRPC). Apalutamide was found to delay the presence of metastases (metastases free survival-MFS) by approximately 2 years versus placebo in M0 CRPC. While overall survival benefit has yet to be established, the MFS benefit is clinically meaningful and urology practices should be equipped to manage patients using this new oral agent. Since the majority of patients remain under urologic care when this disease stage develops and because the drug is straightforward to administer, urology practices are ideal to identify and treat. The objective of this brief article is to discuss the typical patient profile for use of apalutamide and to review the pros and cons of use and common side effects and management.

Duke Scholars

Published In

Can J Urol

ISSN

1195-9479

Publication Date

June 2019

Volume

26

Issue

3

Start / End Page

9782 / 9786

Location

Canada

Related Subject Headings

  • Treatment Outcome
  • Thiohydantoins
  • Prostatic Neoplasms, Castration-Resistant
  • Practice Guidelines as Topic
  • Neoplasm Staging
  • Male
  • Humans
  • Disease-Free Survival
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Moul, Judd W. “How I do it: Apalutamide use in non-metastatic castrate resistant prostate cancer.Can J Urol 26, no. 3 (June 2019): 9782–86.
Moul, Judd W. “How I do it: Apalutamide use in non-metastatic castrate resistant prostate cancer.Can J Urol, vol. 26, no. 3, June 2019, pp. 9782–86.

Published In

Can J Urol

ISSN

1195-9479

Publication Date

June 2019

Volume

26

Issue

3

Start / End Page

9782 / 9786

Location

Canada

Related Subject Headings

  • Treatment Outcome
  • Thiohydantoins
  • Prostatic Neoplasms, Castration-Resistant
  • Practice Guidelines as Topic
  • Neoplasm Staging
  • Male
  • Humans
  • Disease-Free Survival
  • 3202 Clinical sciences
  • 1103 Clinical Sciences